News and Views
Nature Chemical Biology 2, 658 - 659 (2006)
doi:10.1038/nchembio1206-658
Puzzling through fragment-based drug design
Philip J Hajduk1
- Philip J. Hajduk is in the Department of Advanced Technology, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA.e-mail: philip.hajduk@abbott.com
Abstract
Fragment-based drug design capitalizes on the modular binding of low-molecular-weight, low-affinity ligands. However, the deconstruction of lead-like inhibitors into putative fragments reveals the surprising complexity of dealing with low-affinity leads, thereby challenging oversimplification of these leads and highlighting the richness of their chemical diversity and molecular recognition.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
A new school for screeningNature Biotechnology News and Views (01 Feb 2005)
Fragment-based drug discovery takes a virtual turnNature Chemical Biology News and Views (01 May 2009)
RESEARCH
Impact of linker strain and flexibility in the design of a fragment-based inhibitorNature Chemical Biology Article (01 Jun 2009)
Molecular docking and ligand specificity in fragment-based inhibitor discoveryNature Chemical Biology Article (01 May 2009)
See all 4 matches for Research
